Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | TP53 |
Variant | S215G |
Impact List | missense |
Protein Effect | loss of function |
Gene Variant Descriptions | TP53 S215G lies within the DNA-binding domain of the Tp53 protein (PMID: 15510160). S215G results in decreased Tp53 transactivation activity and leads to reduced apoptosis relative to wild type Tp53 in cell culture (PMID: 22862161). |
Associated Drug Resistance | |
Category Variants Paths |
TP53 mutant TP53 exon6 TP53 S215G TP53 mutant TP53 inact mut TP53 S215G |
Transcript | NM_000546.6 |
gDNA | chr17:g.7674888T>C |
cDNA | c.643A>G |
Protein | p.S215G |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
NM_001126112.2 | chr17:g.7674888T>C | c.643A>G | p.S215G | RefSeq | GRCh38/hg38 |
NM_001407266.1 | chr17:g.7674888T>C | c.643A>G | p.S215G | RefSeq | GRCh38/hg38 |
NM_001126114.2 | chr17:g.7674888T>C | c.643A>G | p.S215G | RefSeq | GRCh38/hg38 |
NM_000546 | chr17:g.7674888T>C | c.643A>G | p.S215G | RefSeq | GRCh38/hg38 |
NM_000546.5 | chr17:g.7674888T>C | c.643A>G | p.S215G | RefSeq | GRCh38/hg38 |
NM_001407262.1 | chr17:g.7674888T>C | c.643A>G | p.S215G | RefSeq | GRCh38/hg38 |
NM_001126112.3 | chr17:g.7674888T>C | c.643A>G | p.S215G | RefSeq | GRCh38/hg38 |
NM_001126113 | chr17:g.7674888T>C | c.643A>G | p.S215G | RefSeq | GRCh38/hg38 |
NM_001126113.3 | chr17:g.7674888T>C | c.643A>G | p.S215G | RefSeq | GRCh38/hg38 |
NM_000546.6 | chr17:g.7674888T>C | c.643A>G | p.S215G | RefSeq | GRCh38/hg38 |
NM_001126114.3 | chr17:g.7674888T>C | c.643A>G | p.S215G | RefSeq | GRCh38/hg38 |
NM_001126113.2 | chr17:g.7674888T>C | c.643A>G | p.S215G | RefSeq | GRCh38/hg38 |
NM_001407264.1 | chr17:g.7674888T>C | c.643A>G | p.S215G | RefSeq | GRCh38/hg38 |
NM_001126114 | chr17:g.7674888T>C | c.643A>G | p.S215G | RefSeq | GRCh38/hg38 |
NM_001126112 | chr17:g.7674888T>C | c.643A>G | p.S215G | RefSeq | GRCh38/hg38 |
NM_001407268.1 | chr17:g.7674888T>C | c.643A>G | p.S215G | RefSeq | GRCh38/hg38 |
NM_001407270.1 | chr17:g.7674888T>C | c.643A>G | p.S215G | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
TP53 P98fs TP53 R175C TP53 S215G | ovarian cancer | predicted - resistant | Adavosertib + Carboplatin | Case Reports/Case Series | Actionable | In a Phase II trial, Paraplatin (carboplatin) and Adavosertib (MK-1775) combination treatment resulted in disease progression in an ovarian cancer patient harboring TP53 P98fs, R175C, and S215G (PMID: 27998224; NCT01164995). | 27998224 |